Literature DB >> 28629552

Comparative Analysis of Four Scores to Stratify Patients With Heart Failure and Reduced Ejection Fraction.

Pedro Freitas1, Carlos Aguiar2, António Ferreira2, António Tralhão2, António Ventosa2, Miguel Mendes2.   

Abstract

There are several prognostic risk scores available for patients with heart failure with reduced ejection fraction (HFrEF) that can aid in the decision of listing candidates for heart transplant (HTx). A direct comparison between these scores has not been performed. Therefore, our objective was to evaluate the calibration and discriminative power of 4 contemporary HF scores. A retrospective analysis of 259 patients with HFrEF who underwent cardiopulmonary exercise test was conducted. The Heart Failure Survival Score (HFSS), Seattle Heart Failure Model (SHFM), Meta-analysis Global Group in Chronic Heart Failure (MAGGIC), and Metabolic Exercise Cardiac Kidney Index (MECKI) were compared. During the first year, 7 deaths occurred (6 cardiovascular) and 25 patients were submitted to HTx (8 urgent). Over a 2-year period, 14 deaths occurred (10 cardiovascular) and 34 patients received an HTx (8 urgent). Calibration analysis showed that SHFM and HFSS tended to underestimate event occurrence, whereas MAGGIC and MECKI tended to overestimate risk, especially in the highest risk subgroups. Interestingly, MECKI score at 1 year was well calibrated (expected similar to observed events). Overall, the MECKI score consistently showed better discrimination ability for all studied end points (areas under the curve between 0.8 and 0.9). In conclusion, along with HFSS and SHFM, the MECKI score can also be used to aid treatment decisions, such as HTx listing with the advantage of being very well calibrated at 1-year intervals, which might allow us to avoid the pitfalls of under/overestimation of risk.
Copyright © 2017. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2017        PMID: 28629552     DOI: 10.1016/j.amjcard.2017.04.047

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

1.  The Utility of Pentraxin and Modified Prognostic Scales in Predicting Outcomes of Patients with End-Stage Heart Failure.

Authors:  Wioletta Szczurek-Wasilewicz; Michał Skrzypek; Ewa Romuk; Mariusz Gąsior; Bożena Szyguła-Jurkiewicz
Journal:  J Clin Med       Date:  2022-05-04       Impact factor: 4.964

Review 2.  The New Heart Failure Association Definition of Advanced Heart Failure.

Authors:  Marco Metra; Elisabetta Dinatolo; Nicolò Dasseni
Journal:  Card Fail Rev       Date:  2019-02

3.  The MECKI score initiative: Development and state of the art.

Authors:  Elisabetta Salvioni; Alice Bonomi; Federica Re; Massimo Mapelli; Irene Mattavelli; Giuseppe Vitale; Filippo M Sarullo; Pietro Palermo; Fabrizio Veglia; Piergiuseppe Agostoni
Journal:  Eur J Prev Cardiol       Date:  2020-12       Impact factor: 7.804

Review 4.  Comparison among different multiparametric scores for risk stratification in heart failure patients with reduced ejection fraction.

Authors:  Ugo Corrà; Alessandra Magini; Stefania Paolillo; Maria Frigerio
Journal:  Eur J Prev Cardiol       Date:  2020-12       Impact factor: 7.804

5.  Performance of Prognostic Risk Scores in Elderly Chinese Patients with Heart Failure.

Authors:  Yalin Cheng; Ke Chai; Wanrong Zhu; Yuhao Wan; Yaodan Liang; Minghui Du; Yingying Li; Ning Sun; Jiefu Yang; Hua Wang
Journal:  Clin Interv Aging       Date:  2021-09-16       Impact factor: 4.458

6.  Heart failure mortality prediction using PRISM score and development of a classification and regression tree model to refer patients for palliative care consultation.

Authors:  Sindhu Avula; Michael LaFata; Mohammed Nabhan; Ambreen Allana; Bhavana Toprani; Caleb Scheidel; Anupam Suneja
Journal:  Int J Cardiol Heart Vasc       Date:  2019-12-13

7.  Cardiopulmonary Exercise Test in the Evaluation of Heart Transplant Candidates with Atrial Fibrillation.

Authors:  Miguel Mendes
Journal:  Arq Bras Cardiol       Date:  2020-02       Impact factor: 2.000

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.